secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001736730-25-000041
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 reports SYNGAP1 protein increase in NHPs and favorable Phase 1 safety data for UCD program at ASGCT
--------------------------------------------------------------------------------

- CMP-SYNGAP-01 restored SYNGAP1 protein to near-normal in haploinsufficient mice and rescued motor/learning defects.
- In NHPs, biweekly intrathecal CMP-SYNGAP-01 achieved ~1.5-fold SYNGAP1 increase in relevant brain regions.
- Phase 1 SAD data for CMP-CPS-001 in 48 healthy volunteers: well tolerated, no serious AEs, dose-dependent PK.
- UCD preclinical: CMP-CPS-001 increased ureagenesis up to 40% in NHPs and reduced ammonia in mice.
- Company plans to expand Phase 1 into OTC heterozygotes with reduced urea cycle function.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000041/0001736730-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000041/camp-20250516.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer